The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases reported that the licensing partner for its FLT3+Aurora kinase programme (FLT 3 programme) has decided not to exercise its option to continue the development of the programme. Worldwide rights to the FLT3 programme, as well as data relating to progress made by the Licensee, will therefore revert to Sareum.
